Lyell Immunopharma Announces Participation in May Investor Conferences
Rhea-AI Summary
Lyell Immunopharma (Nasdaq: LYEL) announced that senior management will join two May 2026 investor events focused on oncology.
They will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference/b) on May 19 and the on May 20, with live and replay webcasts on the investor website.
Positive
- None.
Negative
- None.
News Market Reaction – LYEL
In the May 12 session, LYEL gained 0.26%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Positive | -3.8% | Q1 2026 results, pipeline progress and cash runway update. |
| Apr 07 | Investor conference | Neutral | +0.4% | Announcement of Needham virtual healthcare conference presentation and webcast. |
| Mar 12 | FY 2025 earnings | Negative | -14.2% | Q4 and 2025 results with large net loss and program updates. |
| Mar 09 | Private placement tranche | Positive | +13.5% | Closing of additional $50M equity tranche and new CFO/COO appointment. |
| Feb 23 | Investor conferences | Neutral | +6.1% | Participation in multiple March investor conferences with webcasts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings updates have often seen negative next-day moves, while financing milestones and some conference participation headlines have coincided with positive reactions.
Over the last few months, Lyell reported Q4 2025 and Q1 2026 results, highlighting progress in its PiNACLE and LYL273 programs and significant net losses, with mixed share-price reactions. A $50 million private placement tranche closing on Mar 9, 2026 produced a strong positive move, while the May 6, 2026 Q1 update saw shares decline. March and April conference-participation announcements with webcasts, similar in nature to this May investor conference news, drew modestly positive responses, suggesting routine but constructive investor-relations activity.
Key Terms
chimeric antigen receptor (car) t-cell therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences:
- H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time
- 2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time
A live webcast of each fireside chat can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of each webcast will be available on the Company's website following each event.
About Lyell Immunopharma, Inc.
Lyell is a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to arm CAR T cells with enhancements needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. LyFE has commercial launch capability and is expected to have the capacity to manufacture more than 1,200 CAR T-cell doses per year. To learn more, please visit www.lyell.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: Lyell management’s planned participation at investor conferences; the potential clinical benefits and therapeutic potential of Lyell’s product candidates; and the sufficiency of the capacity of LyFE to manufacture drug supply through potential commercial launch. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties described under the heading “Risk Factors” in Lyell’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 6, 2026. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.
Contact:
Pablo Fenton
Associate Director, Investor Relations and Corporate Communications
pfenton@lyell.com
